Navitus Health Solutions Achieves an Industry-Leading PMPM Trend for 2017

April 23, 2018

MADISON, Wis., April 23, 2018 — Navitus Health Solutions, a full pass-through pharmacy benefits company, released its 2017 drug trend report today stating that it continued to provide substantially lower costs for its clients in 2017, achieving an industry leading net cost per member per month (PMPM) of $76.56 across its commercial business, which is 15.5 percent lower than the industry average of $90.66 PMPM. The report also states that Navitus’ trend management efforts have resulted in a cumulative savings of $62.35 PMPM over the past five years, compared to the industry average.

“We’re committed to taking the unnecessary costs out of pharmacy benefits and to making prescriptions more affordable for both our clients and their members,” said Tom Pabich, SVP of Business Development and Client Services. “And we’re very pleased that in an industry challenged with price inflation and specialty drug utilization increases that we were able to help our clients reduce their costs.”

Other key highlights from the report include:

  • Forty-percent of clients experienced a negative PMPM trend
  • Clients new to Navitus in 2017 saved an average of 17 percent in drug cost
  • Plan sponsors from a wide variety of industries that transitioned to Navitus and adopted recommended cost-reduction strategies, achieved a significant PMPM trend savings of up to 30 percent

Navitus attributes its success in managing to a low PMPM to its unique pass-through approach combined with a lowest-net cost philosophy and quality clinical care model. In addition, clients can choose from a variety of cost-reduction strategies ranging from network management and generics, to formulary management and specialty pharmacy to gain greater control over expenses and provide clinical support to improve member health.

“Our unique pass-through model is what ultimately enables us to provide greater savings and full alignment with our valued clients,” Pabich said. “Using this model, we pass 100 percent of pharmacy network discounts and manufacturer rebates directly to our clients.”

“We’re pleased with the positive results we’ve been able to achieve for our clients in 2017,” said Brent Eberle, SVP and Chief Pharmacy Officer. “However, we know the challenge to manage costs and improve health is far from over. With specialty pharmacy spend continuing to grow over the next few years and several potential cost drivers on the horizon including treatments for anti-migraine, oncology and multiple sclerosis, we will be working diligently to continue to innovate and refine solutions to better meet our clients’ needs.”

To get a copy of the Navitus Health Solutions 2017 Drug Trend Report, here.

About Navitus

Navitus Health Solutions, LLC, a subsidiary of SSM Healthcare Corporation, is a full-service, URAC-accredited pharmacy benefit management company. As a zero-spread, full pass through pharmacy benefit manager (PBM), Navitus aligns performance with plan sponsors’ benefit goals to deliver comprehensive clinical programs and cost-saving strategies that lower drug trend and promote good member health. Navitus provides its flexible services to government entities, self-funded employers, coalitions, labor organizations, third-party administrators, and health plans, including managed Medicaid, Exchanges, and Medicare Part D. For more information about Navitus’ solutions to rising health care costs, visit www.navitus.com or call 877-571-7500.

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Examining Trends that Drive Informed Decisions

Now Available: 8th Annual Drug Trend Report

See the latest results and access industry insights you need to navigate current trend drivers.

Related blogs

Navigating Healthcare and Improving Outcomes

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

In this overview of our national Legal Ease webinar event, we highlight key federal and state developments shaping the conversation around PBM reform – and what they mean for your clients.  …

Navigating the Drug Supply Chain: What You Need to Know

Navigating the Drug Supply Chain: What You Need to Know

Before a prescription ever reaches a pharmacy counter, it has already moved through a complex ecosystem known as the drug supply chain. From manufacturers and wholesalers to pharmacy benefit managers (PBMs) and pharmacies, each entity plays a role in…

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Authors: Justin Arzt, PharmD; Agata Siwak, PharmD, MSBA; Marnie Wickizer, PharmD, AE-C, CDCES; Ryan Schmidt, PharmD; Robert Topp, RN, PhD; Matt Hustad, PharmD All authors are employees of Navitus Health Solutions. Abstract Adalimumab biosimilar adoption…

PBM 101: Why the Model Matters

PBM 101: Why the Model Matters

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are conduits of expertise, analytics and savings opportunities, poised to deliver exceptional health care while driving down costs. They coordinate between drug manufacturers,…

Associate Resource Group Spotlight: Green Team

Associate Resource Group Spotlight: Green Team

The Green Team believes that small changes lead to significant impact. Whether its reducing waste, conserving energy or implementing eco-friendly initiatives, they serve as an internal hub for expertise regarding environmental sustainability….

PBM 101: The Three PBM Business Models

PBM 101: The Three PBM Business Models

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are regarded by the media as intermediaries between drug manufacturers, pharmacies, health plans and plan sponsors. But they’re so much more than that. PBMs act as conduits…

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….

Achieving Outstanding Results with Tailored Network Strategies

Achieving Outstanding Results with Tailored Network Strategies

A medium-sized city in Michigan with 1,350 members was seeking ways to lower its pharmacy benefit costs, which were growing under its existing traditional pharmacy benefit manager (PBM). With its member covered by a two-tier, open formulary including…

previous arrow
next arrow